Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 52.2% in July

Dyadic International Inc. (NASDAQ:DYAI) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 83,534 shares, a drop of 52.2% from the June 30th total of 174,705 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily volume of 326,346 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Dyadic International

Several hedge funds have recently bought and sold shares of DYAI. Bank of America Corp DE grew its position in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the 3rd quarter worth approximately $190,000. Marathon Capital Management increased its stake in Dyadic International by 142.9% in the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares in the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dyadic International currently has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Price Performance

DYAI stock traded down $0.02 during midday trading on Tuesday, hitting $1.11. The company’s stock had a trading volume of 280,761 shares, compared to its average volume of 181,173. Dyadic International has a 12 month low of $0.65 and a 12 month high of $1.60. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm has a market capitalization of $40.45 million, a price-to-earnings ratio of -4.87 and a beta of 1.15. The company has a 50 day moving average of $0.90 and a two-hundred day moving average of $0.85.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. On average, analysts expect that Dyadic International will post 0.13 EPS for the current year.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.